

# Graham Rena

## List of Publications by Year in descending order

Source: <https://exaly.com/author-pdf/6760091/publications.pdf>

Version: 2024-02-01

38  
papers

5,610  
citations

304368

22  
h-index

301761

39  
g-index

39  
all docs

39  
docs citations

39  
times ranked

8297  
citing authors

#	ARTICLE	IF	CITATIONS
1	Left Ventricular Hypertrophy in Diabetic Cardiomyopathy: A Target for Intervention. <i>Frontiers in Cardiovascular Medicine</i> , 2021, 8, 746382.	1.1	23
2	Metformin: still the sweet spot for CV protection in diabetes?. <i>Current Opinion in Pharmacology</i> , 2020, 54, 202-208.	1.7	11
3	In a cohort of individuals with type 2 diabetes using the drug sulfasalazine, HbA 1c lowering is associated with haematological changes. <i>Diabetic Medicine</i> , 2020, 38, e14463.	1.2	1
4	Editorial: Metformin: Beyond Diabetes. <i>Frontiers in Endocrinology</i> , 2019, 10, 851.	1.5	12
5	Repurposing Metformin for Cardiovascular Disease. <i>Circulation</i> , 2018, 137, 422-424.	1.6	100
6	Metformin selectively targets redox control of complex I energy transduction. <i>Redox Biology</i> , 2018, 14, 187-197.	3.9	115
7	Heart failure and diabetes: metabolic alterations and therapeutic interventions: a state-of-the-art review from the Translational Research Committee of the Heart Failure Association of the European Society of Cardiology. <i>European Heart Journal</i> , 2018, 39, 4243-4254.	1.0	171
8	Regulation of hepatic glucose production and AMPK by AICAR but not by metformin depends on drug uptake through the equilibrative nucleoside transporter 1 (ENT1). <i>Diabetes, Obesity and Metabolism</i> , 2018, 20, 2748-2758.	2.2	10
9	The mechanisms of action of metformin. <i>Diabetologia</i> , 2017, 60, 1577-1585.	2.9	1,421
10	New Evidence for the Mechanism of Action of a Type-2 Diabetes Drug Using a Magnetic Bead-Based Automated Biosensing Platform. <i>ACS Sensors</i> , 2017, 2, 1329-1336.	4.0	7
11	Investigation of salicylate hepatic responses in comparison with chemical analogues of the drug. <i>Biochimica Et Biophysica Acta - Molecular Basis of Disease</i> , 2016, 1862, 1412-1422.	1.8	8
12	Anti-Inflammatory Effects of Metformin Irrespective of Diabetes Status. <i>Circulation Research</i> , 2016, 119, 652-665.	2.0	498
13	The copper binding properties of metformin as QCM-D, XPS and nanobead agglomeration. <i>Chemical Communications</i> , 2015, 51, 17313-17316.	2.2	20
14	Biomolecular Mode of Action of Metformin in Relation to Its Copper Binding Properties. <i>Biochemistry</i> , 2014, 53, 787-795.	1.2	46
15	Salicylic acid: old and new implications for the treatment of type 2 diabetes?. <i>Diabetology International</i> , 2014, 5, 212-218.	0.7	16
16	Molecular mechanism of action of metformin: old or new insights?. <i>Diabetologia</i> , 2013, 56, 1898-1906.	2.9	376
17	The anti-neurodegenerative agent clioquinol regulates the transcription factor FOXO1a. <i>Biochemical Journal</i> , 2012, 443, 57-64.	1.7	9
18	Cellular Responses to the Metal-Binding Properties of Metformin. <i>Diabetes</i> , 2012, 61, 1423-1433.	0.3	85

#	ARTICLE	IF	CITATIONS
19	Molecular action and pharmacogenetics of metformin: current understanding of an old drug. <i>Diabetes Management</i> , 2012, 2, 439-452.	0.5	15
20	Zinc-dependent effects of small molecules on the insulin-sensitive transcription factor FOXO1a and gluconeogenic genes. <i>Metallomics</i> , 2010, 2, 195-203.	1.0	21
21	Black tea polyphenols mimic insulin/insulin-like growth factor-1 signalling to the longevity factor FOXO1a. <i>Aging Cell</i> , 2008, 7, 69-77.	3.0	50
22	Epigallocatechin gallate (EGCG) mimics insulin action on the transcription factor FOXO1a and elicits cellular responses in the presence and absence of insulin. <i>Cellular Signalling</i> , 2007, 19, 378-383.	1.7	63
23	D4476, a cell-permeant inhibitor of CK1, suppresses the site-specific phosphorylation and nuclear exclusion of FOXO1a. <i>EMBO Reports</i> , 2004, 5, 60-65.	2.0	232
24	Insulin Regulation of Insulin-like Growth Factor-binding Protein-1 Gene Expression Is Dependent on the Mammalian Target of Rapamycin, but Independent of Ribosomal S6 Kinase Activity. <i>Journal of Biological Chemistry</i> , 2002, 277, 9889-9895.	1.6	40
25	Two novel phosphorylation sites on FKHR that are critical for its nuclear exclusion. <i>EMBO Journal</i> , 2002, 21, 2263-2271.	3.5	205
26	Molecular Cloning, Genomic Positioning, Promoter Identification, and Characterization of the Novel Cyclic AMP-Specific Phosphodiesterase PDE4A10. <i>Molecular Pharmacology</i> , 2001, 59, 996-1011.	1.0	70
27	Roles of the forkhead in rhabdomyosarcoma (FKHR) phosphorylation sites in regulating 14-3-3 binding, transactivation and nuclear targeting. <i>Biochemical Journal</i> , 2001, 354, 605.	1.7	152
28	Antagonistic effects of phorbol esters on insulin regulation of insulin-like growth factor-binding protein-1 (IGFBP-1) but not glucose-6-phosphatase gene expression. <i>Biochemical Journal</i> , 2001, 359, 611.	1.7	10
29	Roles of the forkhead in rhabdomyosarcoma (FKHR) phosphorylation sites in regulating 14-3-3 binding, transactivation and nuclear targeting. <i>Biochemical Journal</i> , 2001, 354, 605-612.	1.7	227
30	The kinase DYRK1A phosphorylates the transcription factor FKHR at Ser329 in vitro, a novel in vivo phosphorylation site. <i>Biochemical Journal</i> , 2001, 355, 597-607.	1.7	247
31	Antagonistic effects of phorbol esters on insulin regulation of insulin-like growth factor-binding protein-1 (IGFBP-1) but not glucose-6-phosphatase gene expression. <i>Biochemical Journal</i> , 2001, 359, 611-619.	1.7	15
32	Membrane Localization of Cyclic Nucleotide Phosphodiesterase 3 (PDE3). <i>Journal of Biological Chemistry</i> , 2000, 275, 38749-38761.	1.6	94
33	Phosphorylation of the Transcription Factor Forkhead Family Member FKHR by Protein Kinase B. <i>Journal of Biological Chemistry</i> , 1999, 274, 17179-17183.	1.6	639
34	Phosphorylation of Serine 256 by Protein Kinase B Disrupts Transactivation by FKHR and Mediates Effects of Insulin on Insulin-like Growth Factor-binding Protein-1 Promoter Activity through a Conserved Insulin Response Sequence. <i>Journal of Biological Chemistry</i> , 1999, 274, 17184-17192.	1.6	491
35	Upregulation of cAMP-specific PDE-4 activity following ligation of the TCR complex on thymocytes is blocked by selective inhibitors of protein kinase C and tyrosyl kinases. <i>Cell Biochemistry and Biophysics</i> , 1998, 28, 161-185.	0.9	9
36	Identification and characterization of the human homologue of the short PDE4A cAMP-specific phosphodiesterase RD1 (PDE4A1) by analysis of the human HSPDE4A gene locus located at chromosome 19p13.2. <i>Biochemical Journal</i> , 1998, 333, 693-703.	1.7	45

#	ARTICLE	IF	CITATIONS
37	Intracellular localization of the PDE4A cAMP-specific phosphodiesterase splice variant RD1 (RNPDE4A1A) in stably transfected human thyroid carcinoma FTC cell lines. <i>Biochemical Journal</i> , 1997, 321, 177-185.	1.7	36
38	Receptor-mediated stimulation of lipid signalling pathways in CHO cells elicits the rapid transient induction of the PDE1B isoform of Ca <sup>2+</sup> /calmodulin-stimulated cAMP phosphodiesterase. <i>Biochemical Journal</i> , 1997, 321, 157-163.	1.7	19